Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin Of India Counts On Global Generics Push To Increase Profits

This article was originally published in PharmAsia News

Executive Summary

The expansion by India's Lupin into U.S. and Japan markets is generating a company forecast of an increase of as much as 37 percent in profit and sales during the current financial year. Lupin is relying on the push in the world's two largest markets to get patients to use generics to drive its profit increase. The global market for generics is growing at double that of branded drugs because of perceived government needs to trim expenses. Lupin Managing Director Kamal Sharma said his company also plans to acquire more firms and technology to help meet the global demand. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts